A genome-wide cfDNA methylation enrichment method (cfMeDIP-seq) enables response monitoring using plasma alone, avoiding ...

The FDA has granted Fast Track Designation to AKY-1189 (actinium-225; 225 Ac) a potent alpha-emitting radioisotope in the ...

The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores ...

In this opening segment, Dr. Marwan Fakih and Dr. Richard Kim outline the current epidemiology, biology, and therapeutic ...

TTLC 2026 spotlights next-gen lung cancer therapies, co-mutation strategies, and ctDNA monitoring—insights beyond CME for what’s coming next.

CD123 is universally and highly expressed on BPDCN cells. Because CD123 expression is significantly lower on normal hematopoietic stem cells, it provides a distinct "therapeutic window," allowing for ...

Lane noted that as the landscape progresses, by maintaining high vigilance for symptoms, adhering to safety protocols, and fostering academic partnerships, the oncologists can continue to transform ...

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.

Unlike IMiDs, which typically induce cytostatic growth arrest, the accelerated degradation achieved by CELMoDs leads directly to cell death. This shift from stopping growth to actively killing myeloma ...

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

Tentative approval for PNT2003 positions it as the first FDA-cleared radioequivalent of Lu 177 dotatate, with anticipated ...

Erica Pimenta, MD, PhD, is an instructor at Harvard Medical School and physician-scientist at Dana-Farber Cancer Institute Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her ...